CD274 and head and neck squamous cell carcinoma: The anti-PD-1 antibody pembrolizumab exhibited antitumor activity in patients with refractory squamous cell carcinoma of the head and neck cancer (SCCHN), whose tumors expressed ≥1 % PD-L1 (RR = 20 % in 56 patients) [44].